---
title: "T 细胞为什么会累垮？北大邓觅团队揭秘！这些免疫细胞才是真正的耗竭推手！"
date: 2026-02-09T13:36:19Z
draft: ["false"]
tags: [
  "fetched",
  "芒果师兄"
]
categories: ["Acdemic"]
---
T 细胞为什么会累垮？北大邓觅团队揭秘！这些免疫细胞才是真正的耗竭推手！ by 芒果师兄
------
<div><p data-pm-slice="4 4 []"><b><font face="微软雅黑"><span leaf=""><span textstyle="">T 细胞耗竭在多种疾病中都具有重要作用</span></span></font></b><font face="微软雅黑"><span leaf=""><span textstyle="">。</span></span></font><span data-pm-slice="0 0 []"><strong><span leaf=""><span textstyle="">在慢性感染时</span></span></strong></span><span><span leaf=""><span textstyle="">，效应 T 细胞产生后，抗原和炎症仍然存在，免疫系统和病原体相互对抗而进入一个漫长的僵局，没有一方能够获得优势。然而，在一段时间后，免疫细胞被耗竭而让病原体获得优势，</span></span></span><span><strong><span leaf=""><span textstyle="">T 细胞逐渐失去效应功能，记忆 T 细胞特征也开始缺失，即 T 细胞耗竭（T Cell Exhaustion）</span></span></strong></span><span><span leaf=""><span textstyle="">。而</span><span textstyle="">肿瘤抗原的长期刺激，也会导致 T 细胞耗竭</span><span textstyle="">。</span></span></span></p><section nodeleaf=""><img data-src="https://mmbiz.qpic.cn/mmbiz_png/dfG8WuibrvaeTBgiaPibZ1zH6wKKuYEKjnjKTW8on4x6faF5rLX3lALN5gCE0Iz1X9foNibc2cFKBRhQUmiaDCvpTHCsVHhYqgRlEeqzXQ0IQWRo/640?wx_fmt=png&amp;from=appmsg" data-ratio="0.3574074074074074" data-s="300,640" data-type="png" data-w="1080" type="block" data-backw="578" data-backh="206" data-imgfileid="100093337" data-aistatus="1" src="https://mmbiz.qpic.cn/mmbiz_png/dfG8WuibrvaeTBgiaPibZ1zH6wKKuYEKjnjKTW8on4x6faF5rLX3lALN5gCE0Iz1X9foNibc2cFKBRhQUmiaDCvpTHCsVHhYqgRlEeqzXQ0IQWRo/640?wx_fmt=png&amp;from=appmsg"></section><p><span leaf="" mpa-font-style="mldpr7oyk80">2024年12月，<span textstyle="">北京大学邓觅教授团队</span>在Chinese Journal of Cancer Research期刊发表题目为Myeloid cells meet CD8⁺ T cell exhaustion in cancer: What, why and how的综述论文，系统梳理了<span textstyle="">髓系细胞如何在肿瘤微环境中驱动CD8⁺ T 细胞耗竭功能</span>这一关键性科学问题。该文不仅具有高度学术整合性，更对临床免疫治疗策略的优化提供重要启示。</span></p><section nodeleaf=""><img data-src="https://mmbiz.qpic.cn/mmbiz_png/dfG8Wuibrvad6hvKDmvicazdRllljHWh8vycG5Jiaw65zDUGibQKOsQ980UExbiboFVGDvt0olbrMhwd6LkiasHArX9nVGVAgicKuVg4swQKeQ97xk/640?wx_fmt=png&amp;from=appmsg" data-ratio="0.46944444444444444" data-s="300,640" data-type="png" data-w="1080" type="block" data-backw="578" data-backh="271" data-imgfileid="100093336" data-aistatus="1" src="https://mmbiz.qpic.cn/mmbiz_png/dfG8Wuibrvad6hvKDmvicazdRllljHWh8vycG5Jiaw65zDUGibQKOsQ980UExbiboFVGDvt0olbrMhwd6LkiasHArX9nVGVAgicKuVg4swQKeQ97xk/640?wx_fmt=png&amp;from=appmsg"></section><p><span leaf="" mpa-font-style="mldpr7oyk80"><span textstyle="">文章首先追溯了 T 细胞耗竭概念的起源</span>。从1977年在鼻咽癌患者中首次观察到无反应性CD8⁺ T 细胞，到2008年正式定义exhausted T cell（Tex），再到通过单细胞技术揭示其高度异质性。值得注意的是，作者明确区分功能性耗竭（effector function loss）与克隆性耗竭（clonal deletion），并指出 T 细胞失能状态还包括无能（anergy）、衰老（senescence）和应激响应 T 细胞（TSTR）。这些状态表型重叠但机制迥异，提醒我们在评估免疫治疗效果时，不能仅凭PD-1或IFN-γ等单一指标下结论，而需多维度精准刻画T细胞状态。</span></p><section nodeleaf=""><img data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/dfG8WuibrvadxYWGLvke4GIK6kpfP00aZHEckx6lllzgJxXKuQCfmyibWNnhSmJG8YvaTkYgooZSdY8B6Ey9AQowbibic21tTiacIzrp4BB0WXm4/640?wx_fmt=png&amp;from=appmsg" data-ratio="1.3850687622789783" data-s="300,640" data-type="png" data-w="1018" type="block" data-backw="578" data-backh="801" data-imgfileid="100093338" data-aistatus="1" src="https://mmbiz.qpic.cn/sz_mmbiz_png/dfG8WuibrvadxYWGLvke4GIK6kpfP00aZHEckx6lllzgJxXKuQCfmyibWNnhSmJG8YvaTkYgooZSdY8B6Ey9AQowbibic21tTiacIzrp4BB0WXm4/640?wx_fmt=png&amp;from=appmsg"></section><p><span leaf="" mpa-font-style="mldpr7oy21qb">该综述的核心在于系统阐明三类主要髓系细胞，肿瘤相关巨噬细胞（TAMs）、树突状细胞（DCs）和中性粒细胞（Neutrophils）如何通过多重机制诱导CD8⁺ Tex形成。</span></p><section nodeleaf=""><img data-src="https://mmbiz.qpic.cn/mmbiz_png/dfG8Wuibrvadt1ZzVSE8wowicCHTicWJibaTa87zjZtx7t1wicWraZZ4icYp9Uiahz6MWV0VkCPSZJxzs2HTWh0uUHWaxRVp4RvbV58uzabU6nMWLQ/640?wx_fmt=png&amp;from=appmsg" data-ratio="0.700925925925926" data-s="300,640" data-type="png" data-w="1080" type="block" data-backw="578" data-backh="405" data-imgfileid="100093339" data-aistatus="1" src="https://mmbiz.qpic.cn/mmbiz_png/dfG8Wuibrvadt1ZzVSE8wowicCHTicWJibaTa87zjZtx7t1wicWraZZ4icYp9Uiahz6MWV0VkCPSZJxzs2HTWh0uUHWaxRVp4RvbV58uzabU6nMWLQ/640?wx_fmt=png&amp;from=appmsg"></section><p><span leaf="" mpa-font-style="mldpr7oy21qb" data-pm-slice='1 1 ["para",{"tagName":"p","attributes":{"style":"margin-left: 0px;margin-right: 0px;line-height: 2em;margin-bottom: 24px;"},"namespaceURI":"http://www.w3.org/1999/xhtml"}]'><span textstyle="">TAMs驱动 T 细胞耗竭。</span>TAMs通过高表达MHC-I与 T 细胞TCR形成长效免疫突触，激活IRF4-TOX轴，启动耗竭程序。此外，TAMs是肿瘤微环境中PD-L1的主要来源，通过PD-1/SHP2通路抑制TCR信号，并上调TOX等耗竭转录因子。还通过新型受体通路，如SLAMF7自相互作用可激活STAT1/3，促进YY1、Blimp1等耗竭相关转录因子表达；而VISTA-PSGL-1轴则抑制ERK/AKT/STAT5通路。TAMs高表达Arg1和IDO，消耗精氨酸与色氨酸，削弱 T 细胞活化；更令人关注的是，其产生的衣康酸（itaconate）可通过表观修饰（H3K4me3）上调Eomes，直接驱动PD-1/Tim-3表达。</span></p><section nodeleaf=""><img data-src="https://mmbiz.qpic.cn/mmbiz_png/dfG8WuibrvacxBpWYoP0xVJXHp12FnHyicgjicAYs8tRI0ib5CphwGuaaEs0t8ia98wVkRQ5KUO53EppYdt9fVqKXgAj2R1SlPPiaj2LnktCaDYI8/640?wx_fmt=png&amp;from=appmsg" data-ratio="0.6027777777777777" data-s="300,640" data-type="png" data-w="1080" type="block" data-backw="578" data-backh="348" data-imgfileid="100093341" data-aistatus="1" src="https://mmbiz.qpic.cn/mmbiz_png/dfG8WuibrvacxBpWYoP0xVJXHp12FnHyicgjicAYs8tRI0ib5CphwGuaaEs0t8ia98wVkRQ5KUO53EppYdt9fVqKXgAj2R1SlPPiaj2LnktCaDYI8/640?wx_fmt=png&amp;from=appmsg"></section><p><span leaf=""><br></span></p><p><span leaf="" mpa-font-style="mldpr7oym6r" data-pm-slice='1 1 ["para",{"tagName":"p","attributes":{"style":"margin-left: 0px;margin-right: 0px;line-height: 2em;margin-bottom: 24px;"},"namespaceURI":"http://www.w3.org/1999/xhtml"}]'><span textstyle="">DC亚群的功能极化决定 T 细胞命运。</span>cDCs通过B7H4-Eomes轴、miR-5119下调导致的PD-L1/IDO上调，以及持续的CD137/4-1BB共刺激信号（意外地通过NF-κB/TOX通路促耗竭），均可诱导Tex。pDCs作为I型干扰素（IFN-I）主要来源，IFN-I可破坏Tex脂代谢与氧化还原平衡，推动终末耗竭；同时通过IDO诱导 T 细胞无能，并与Treg互作间接抑制CD8⁺ T 细胞。mregDCs兼具共刺激（CD80-CD28）与共抑制（PD-L1-PD-1、PVR-TIGIT等）功能，选择性地维持祖细胞样Tex（Texprog），这解释为何部分患者对ICB仍有响应。</span></p><p><span leaf=""><br></span></p><section nodeleaf=""><img data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/dfG8WuibrvachHTMEgw9hkPKRgoTtaPOoRQ9IfQzvFEsccP57psvmEAK0r0UxibLUK3OflEkIZlJboKZcNCMJMsLQCtn0UQcFKbRjguVJaPAw/640?wx_fmt=png&amp;from=appmsg" data-ratio="0.612037037037037" data-s="300,640" data-type="png" data-w="1080" type="block" data-backw="578" data-backh="354" data-imgfileid="100093342" data-aistatus="1" src="https://mmbiz.qpic.cn/sz_mmbiz_png/dfG8WuibrvachHTMEgw9hkPKRgoTtaPOoRQ9IfQzvFEsccP57psvmEAK0r0UxibLUK3OflEkIZlJboKZcNCMJMsLQCtn0UQcFKbRjguVJaPAw/640?wx_fmt=png&amp;from=appmsg"></section><p><span leaf="" mpa-font-style="mldpr7oym6r"><span textstyle="">肿瘤相关中性粒细胞TAN与 T 细胞耗竭</span>。PD-L1⁺/PD-L2⁺ TANs可直接抑制CD8⁺ T 细胞增殖与IFN-γ分泌；CD11b介导的胞啃作用（trogocytosis）导致 T 细胞功能紊乱，虽更倾向诱导无能，但可向耗竭演化；NETs（中性粒细胞胞外诱捕网）物理阻隔 T 细胞浸润，其表面高表达PD-L1，可直接诱导Tex表型；Arg1⁺ TANs通过代谢剥夺抑制 T 细胞功能。尽管中性粒细胞寿命短、易碎，研究难度大，但其免疫抑制作用不容低估。</span></p><section nodeleaf=""><img data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/dfG8WuibrvadW4BcMNlGIXIrl7IaSVWkzuX26kHGW1QkfbLLWnEU62AgLXSMK1icd6jB9aYnPzYq1fCWXRB77oxdF1zib3ficN8XCsib8gdDrmYc/640?wx_fmt=png&amp;from=appmsg" data-ratio="0.8287037037037037" data-s="300,640" data-type="png" data-w="1080" type="block" data-imgfileid="100093343" data-aistatus="1" src="https://mmbiz.qpic.cn/sz_mmbiz_png/dfG8WuibrvadW4BcMNlGIXIrl7IaSVWkzuX26kHGW1QkfbLLWnEU62AgLXSMK1icd6jB9aYnPzYq1fCWXRB77oxdF1zib3ficN8XCsib8gdDrmYc/640?wx_fmt=png&amp;from=appmsg"></section><p><span leaf="" mpa-font-style="mldpr7oym6r"><span textstyle="">治疗上，可靶向髓系细胞</span>。如抗CSF1R清除TAMs、阻断IL-1R2减少TAM极化、补充DCs防止终末耗竭、抑制NETs形成等。</span></p><section nodeleaf=""><img data-src="https://mmbiz.qpic.cn/mmbiz_png/dfG8WuibrvafOXZSRL12ecsS8nPSDlYnTFE8eUlGRyFbj5M8WzDtq3LvWYnaHcSCvPFsrWcdqEgs59ia211LzRHW917CMbKyhTASnRwHrDaI4/640?wx_fmt=png&amp;from=appmsg" data-ratio="0.7027777777777777" data-s="300,640" data-type="png" data-w="1080" type="block" data-backw="578" data-backh="406" data-imgfileid="100093344" data-aistatus="1" src="https://mmbiz.qpic.cn/mmbiz_png/dfG8WuibrvafOXZSRL12ecsS8nPSDlYnTFE8eUlGRyFbj5M8WzDtq3LvWYnaHcSCvPFsrWcdqEgs59ia211LzRHW917CMbKyhTASnRwHrDaI4/640?wx_fmt=png&amp;from=appmsg"></section><p><span leaf="" mpa-font-style="mldpr7oym6r">或者直接重编程Tex，包括ICB、细胞因子疗法、代谢/表观干预、CAR-T改造等。尤为值得称道的是，作者强调联合策略的重要性——如抗PD-1 + 抗IL-1R2、ICB + CXCR2抑制剂（阻断中性粒招募）等，在临床前模型中已展现协同效应。</span></p><p><span leaf="" mpa-font-style="mldpr7oy1bsa">这篇综述如同一幅精密的肿瘤免疫调控图，清晰勾勒髓系细胞如何通过受体互作、细胞因子、代谢重编程与表观调控等多维网络，绘制一张抑制CD8⁺ T 细胞的网络图。因此，肿瘤免疫治疗的未来，更在于重塑肿瘤微环境，而非仅激活 T 细胞。</span></p><p><mp-style-type data-value="3"></mp-style-type></p></div>  
<hr>
<a href="https://mp.weixin.qq.com/s/x8Buq7e-KJl4VR3wxdAiZQ",target="_blank" rel="noopener noreferrer">原文链接</a>
